Halozyme Therapeutics, Inc. (HALO) Misses Q4 EPS by 3c; Roche (RHHBY) Triggers $4M Milestone
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.31 -1.71%
EPS Growth %: +30.2%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +30.2%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.41 million versus the consensus estimate of $5.25 million.
Roche (OTCBB: RHHBY) submission trigger $4 million milestone payment.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Roche (OTCBB: RHHBY) submission trigger $4 million milestone payment.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- GameStop beats second quarter estimates on collectibles
- Akari Therapeutics to present ADC platform at five September conferences
Create E-mail Alert Related Categories
Corporate News, Earnings, FDARelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
